Form 4: Maravai LifeSciences Director R. Andrew Eckert Acquires 134,409 Shares of Class A Common Stock Through Restricted Stock Units

Director R. Andrew Eckert of Maravai LifeSciences Holdings, Inc. acquired 134,409 shares of Class A Common Stock through the vesting of restricted stock units.

Summary

• R. Andrew Eckert, a director at Maravai LifeSciences Holdings, Inc., acquired 134,409 shares of Class A Common Stock.
• The acquisition was through the vesting of restricted stock units (RSUs) granted under the company's 2020 Omnibus Incentive Plan.
• One-third of the RSUs vested immediately on the grant date, with the remaining vesting in two equal installments.
• The remaining RSUs will vest on the date of the 2025 Annual Meeting of Shareholders and one year after that date.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed positively as it aligns interests. There are no indications of negative sentiment.

Positives

• The vesting of RSUs aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

This is a standard transaction for a director of a public company, where equity compensation is a common practice to align interests with shareholders.

Comparison to Industry Standards

• Equity compensation, such as RSUs, is a common practice for directors in publicly traded companies like Maravai LifeSciences.
• Companies such as Thermo Fisher Scientific (TMO) and Danaher Corporation (DHR) also use similar equity-based compensation plans for their directors and executives.
• The vesting schedule of one-third immediately and the remainder over two years is a fairly standard approach to incentivize long-term performance and retention.

Stakeholder Impact

• The transaction increases the director's stake in the company, aligning his interests with those of shareholders.
• The vesting schedule encourages long-term commitment from the director, which can be beneficial for the company's performance.

Next Steps

• The remaining RSUs will vest on the date of the 2025 Annual Meeting of Shareholders and one year after that date.

Key Dates

Keywords

Maravai LifeSciences, MRVI, Director, R. Andrew Eckert, Class A Common Stock, Restricted Stock Units, RSUs, Omnibus Incentive Plan, Share Vesting, SEC Form 4